This mid-pregnancy serum biomarker test can accurately and effectively identify pregnancies that will deliver before 32-weeks of gestation.

UCSF researchers have generated and validated a K14-HPV16 transgenic mouse model, in which transgene expression produces neoplastic progression that fully resembles the gynecological and other epithelial dysplastic lesions induced by high risk HPVs. This model offers an invaluable tool for studying HPV infection and developing new drugs for HPV treatment.

This invention is a novel assay to detect and quantify androgen levels, as low as 1.5 ng/dl, in blood or serum samples.

UCSF researchers have identified novel biomarkers of CMV replication that permit early detection of virus transmission before the onset of symptomatic disease. Quantification of these biomarkers is a more sensitive and reliable method than detection of viral DNA and therefore could result in novel tests for diagnosis of congenital infection in early gestation. Additionally, these biomarkers could be used to measure efficacy of treatment in pregnancies at high risk for congenital CMV disease and to serve as endpoints for successful antiviral therapy.